Fast, scalable single-cell testing for blood and tissue samples
Official title: A Uniquely Scalable Platform for Sequencing Tens of Millions of Single Cells from Complex Clinical Samples with a Streamlined Workflow
Funded at Sansimeon, INC · NIH-11255523 · Data updated 2026-11-12
This project builds a fast, easy system to read the genes of millions of individual cells from blood and tissue to help cancer patients and researchers spot rare cells and better match treatments.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sansimeon, INC NIH-funded |
| Lab location | 1 site (Fremont, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $938,335 |
| NIH project number | 2R44GM149003-02 |
| Project ID | NIH-11255523 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be people with cancer or those willing to donate blood or tissue samples for research where detailed cell-level profiling or rare cell detection is useful.
✕Less likely to help
Patients who need only routine lab tests or immediate treatment decisions that do not rely on cell-level genomic profiling are unlikely to benefit directly from this work.
What this research studies
The team is creating an automated, high-throughput platform that isolates and sequences individual cells from whole blood and dissociated tissue using new microfluidic methods. The workflow is designed to be streamlined so clinical labs can process many samples with fewer preparation steps and less bias. Computational tools will be optimized to handle the very large datasets the system produces and improve data fidelity. The platform will be validated using clinically relevant samples, with a focus on applications like rare cell detection, diagnostics, and cancer therapy development.
Why it matters
Potential benefit: If successful, the platform could make single-cell analyses faster and more affordable, improving diagnostic detail, rare tumor cell detection, and treatment selection for patients.
How similar studies have gone: Single-cell sequencing has already provided important clinical insights, but this specific high-throughput, end-to-end platform is a newer, less-tested approach aiming to scale and simplify those methods.
Where this research is happening
-
Sansimeon, INC
Fremont, United States Active
Researchers
- Principal investigator: Spuhler, Philipp Stefan — Sansimeon, INC
- Study coordinator: Spuhler, Philipp Stefan
Related research
Other NIH-funded projects on the same topics.
-
A fast, scalable platform for decoding tens of millions of cells from patient samples
A new high-throughput system helps scientists study very large numbers of cells from patient blood and tumor samples to improve cancer care.
-
Improving cell therapies through advanced single-cell sequencing technology
This study is looking at a new way to improve cancer treatments like CAR-T therapy by examining a lot more immune cells from patients, which could help make these therapies work better and be more affordable for everyone.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.